C Hershko. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Agranulocytosis/chemically inducedDeferiproneDeferoxamine/adverse effectsDeferoxamine/therapeutic useHumansIron Chelating Agents/adverse effectsIron Chelating Agents/therapeutic usePyridones/adverse effectsPyridones/therapeutic useThalassemia/drug therapy
Substances: See more » Iron Chelating AgentsPyridonesDeferiproneDeferoxamine
Year: 1993 PMID: 8096975 DOI: 10.1016/0140-6736(93)92444-x
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321